{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458267412
| IUPAC_name = (''RS'')-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1''H''-benzo[d]imidazole
| image = Lansoprazole.svg
| width = 245
| image2 = Lansoprazole 3D.png
| chirality = [[外消旋混合物|外消旋混合物]]

<!--Clinical data-->
| tradename = Prevacid、EP206 等品牌
| Drugs.com = {{drugs.com|monograph|lansoprazole}}
| pronounce = {{IPAc-en|l|æ|n|ˈ|s|oʊ|p|r|ə|z|oʊ|l}} {{respell|lan|SOH|prə-zohl}}
| MedlinePlus = a695020
| licence_US = Lansoprazole
| pregnancy_AU = B3
| pregnancy_US = B
| legal_US = OTC
| legal_UK = POM
| routes_of_administration = [[口服给药|口服]], [[靜脈注射|IV]]
<!--| class            = [[proton_pump_inhibitor|proton pump inhibitor]]-->

<!--Pharmacokinetic data-->
| bioavailability = 80% 或更多
| protein_bound = 97%
| metabolism = [[肝臟|肝臟]] (由[[CYP3A4|CYP3A4]]-及[[CYP2C19|CYP2C19]]-介導)
| elimination_half-life = 1–1.5 小時
| excretion = [[腎|腎臟]]及[[糞便|排泄物]]

<!--Identifiers-->
| IUPHAR_ligand = 7208
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103577-45-3
| ATC_prefix = A02
| ATC_suffix = BC03
| PubChem = 3883
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00448
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3746
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0K5C5T2QPG
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00355
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6375
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 480

<!--Chemical data-->
| C=16 | H=14 | F=3 | N=3 | O=2 | S=1
| molecular_weight = 369.363 g/mol
| smiles = FC(F)(F)COc1ccnc(c1C)CS(=O)c2[nH]c3ccccc3n2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MJIHNNLFOKEZEW-UHFFFAOYSA-N
}}
{{medical}}
'''蘭索拉唑'''（Lansoprazole），以 Prevacid 等品牌銷售，為一種抑制[[胃|胃]]產生[[胃酸|胃酸]]的藥物。沒有證據表明其有效性與其他[[氫離子幫浦阻斷劑|質子泵抑製劑]]（PPI）的有效性有所不同。<ref name=TI(99)2016>{{cite web|title=[99] Comparative effectiveness of proton pump inhibitors {{!}} Therapeutics Initiative|url=http://www.ti.ubc.ca/2016/06/28/99-comparative-effectiveness-proton-pump-inhibitors/|accessdate=14 July 2016|date=28 June 2016}}</ref>蘭索拉唑早先是通過{{le|鼻胃管插管|Nasogastric intubation|鼻胃管}}給藥，可有效控制胃內的[[pH|pH]]值；主要是為了一些無法吞服固體劑量製劑的病患，而成為靜脈注射[[泮托拉唑|泮托拉唑]]的替代品。<ref name="FrestonChiu2001">{{cite journal|last1=Freston|first1=James|last2=Chiu|first2=Yi-Lin|last3=Pan|first3=Wei-Jian|last4=Lukasik|first4=Nancy|last5=Taubel|first5=Jorg|title=Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously|journal=The American Journal of Gastroenterology|volume=96|issue=7|year=2001|pages=2058–2065|issn=0002-9270|doi=10.1111/j.1572-0241.2001.03939.x|pmid=11467632}}</ref>不過之後已有膠囊服用製劑。<ref>藥物辨識詳細資料,"LANPO CAPSULES 30MG "EVEREST--(EP206)白色長圓柱形"[https://www.fda.gov.tw/MLMS/H0001D2.aspx?LicId=01046246],[[衛生福利部食品藥物管理署|衛生福利部食品藥物管理署]],retrieved at 2019-01-31. </ref>

蘭索拉唑屬於一種[[氫離子幫浦阻斷劑|質子泵抑製劑]]（PPI），與[[奥美拉唑|奥美拉唑]]列在同一藥理學類別。蘭索拉唑已經上市多年，是幾種可用的PPI之一。<ref>http://www.patient.co.uk/showdoc/30002943/</ref> 蘭索拉唑是由[[對映異構體|對映異構體]][[右旋蘭索拉唑|右旋蘭索拉唑]]（Dexilant，以前稱為 Kapidex）與"左旋蘭索拉唑"(levo-lansoprazole)以[[外消旋混合物|外消旋]][1比1]所成之混合藥品。<ref>{{cite web|title=Pharmacy Benefit Update|url=http://epharmacytechnicanschools.com/pharmacy-benefit-update/|accessdate=2 July 2014}}</ref>由於對映異構體的移位，"右旋蘭索拉唑"是由{{le|手性衍生劑|Chiral derivatizing agent|對映體轉變}}而成的對映體純活性成分之商業藥物。蘭索拉唑的血漿消除半衰期（1.5小時）與藥物對人體影響持續的時間不成比例（即[[胃酸|胃酸]]抑制作用）。<ref name="RxList">{{cite web | url = http://www.rxlist.com/cgi/generic/lansop_cp.htm | title = Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism | year = 2007 | accessdate = April 14, 2007 | publisher = RxList.com}}</ref>藥物在使用過一天或更長的時間後，用藥的效果會持續超過24個小時。<ref name="prevacid24hr">{{cite web| url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214713.pdf| title=Prevacid 24HR Label
| date=May 2010| format=PDF| accessdate = November 15, 2014}}</ref>

蘭索拉唑由世界上許多藥品公司以多個品牌來生產。在美國，它於1995年首次獲得[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）的批准上市。<ref name="Mosby's">[http://www.mosbysdrugconsult.com/DrugConsult/Top_200/Drugs/e3230.html Mosby's Drug Consult: Lansoprazole]</ref>而 Prevacid 品牌的專利保護到期日至2009年11月10日止。<ref>[http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=PREVACID&archive=2008 Prevacid drug patents]</ref><ref name="Teva">[http://www.marketwatch.com/story/teva-to-release-prevacid-version-when-patent-expires Teva to release Prevacid version when patent expires]</ref>

==註釋==
{{reflist|2}}

==參見==
*[[亚砜|亚砜]]
*{{le|新藥申請審評程序|New Drug Application}}

==外部連結==
* {{Official website|http://www.prevacid.com/products.aspx|Prevacid official website}} Takeda Pharmaceuticals North America
* {{Official website|http://www.prevacid24hr.com/|Prevacid 24HR official website}} Novartis Consumer Health
* {{Official website|http://www.prevacid.com/products/prevpac-ulcer-treatment.aspx|Prevpac official website}} Takeda Pharmaceuticals North America
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Lansoprazole U.S. National Library of Medicine: Drug Information Portal - Lansoprazole]

{{Drugs for peptic ulcer and GORD}}

[[Category:质子泵抑制剂|Category:质子泵抑制剂]]
[[Category:苯并咪唑|Category:苯并咪唑]]
[[Category:亚砜|Category:亚砜]]
[[Category:吡啶|Category:吡啶]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:三氟甲基化合物|Category:三氟甲基化合物]]